March 24, 2021
Shionogi said on March 23 that its US partner BioAge Labs has commenced a US PII study of its prostaglandin D 2 DP1 receptor antagonist asapiprant (development code: S-555739/BGE-175) for the treatment of COVID-19 in patients aged 60 and above...read more